Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: Differentiation by immunohistochemistry and determining the need for mohs micrographic surgery

Cutis

Volumn 85, Issue 5, 2010, Pages 254-258

  Merritt, Bradley G ^a   Snow, Stephen N ^b   Jack Longley, B ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; DIAGNOSTIC AGENT;

ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CHEMOSURGERY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; SKIN CARCINOMA; SKIN TUMOR; STAINING;

CARCINOMA, BASAL CELL; CARCINOMA, SKIN APPENDAGE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; MALE; MIDDLE AGED; MOHS SURGERY; SKIN NEOPLASMS; STAINING AND LABELING;

EID: 77954012346     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Zeligman I. Solitary trichoepithelioma. Arch Dermatol. 1960;82:35-40.
2. Brownstein MH, Shapiro L. Desmoplastic trichoepithelioma. Cancer. 1977;40:2979-2986.
3. 2 laser destruction of facial adnexal tumors. Dermatol Surg. 1999;25:41-44.
4. Shaffelburg M, Miller R. Treatment of multiple trichoepithelioma with electrosurgery. Dermatol Surg. 1998;24:1154-1156.
5. Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol. 2002;138: 1043-1051.
6. Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer. 1982;50:566-572.
7. Chiller K, Passaro D, Scheuller M, et al. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136:1355-1359.
8. Ohtsuka H, Nagamatsu S. Microcystic adnexal carcinoma: review of 51 Japanese patients. Dermatology. 2002;204:190-193.
9. Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27:401-408.
10. Takei Y, Fukushiro S, Ackerman AB. Criteria for histologic differentiation of desmoplastic trichoepithelioma (sclerosing epithelial hamartoma) from morphea-like basal-cell carcinoma. Am J Dermatopathol. 1985;7:207-221.
11. Costache M, Bresch M, Böer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology. 2008;52:865-876.
12. Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008;21:178-185.
13. Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:295-300.
14. Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34: 782-787.
15. Katona TM, Perkins SM, Billings SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol. 2008;35:174-179.
16. Smith KJ, Williams J, Corbett D, et al. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25:464-471.
17. Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311-315.
18. Basarab T, Orchard G, Russell-Jones R. The use of immunostaining for bcl-2 and CD34 and the lectin peanut agglutinin in differentiating between basal cell carcinomas and trichoepitheliomas. Am J Dermatopathol. 1998;20:448-452.
19. Tellechea O, Reis JP, Domingues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol. 1993;15:452-455.
20. Kist D, Perkins W, Christ S, et al. Anti-human epithelial antigen (Ber-EP4) helps define basal cell carcinoma masked by inflammation. Dermatol Surg. 1997;23: 1067-1070.